<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1715">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622891</url>
  </required_header>
  <id_info>
    <org_study_id>SVU-MED-CHT019-420860</org_study_id>
    <nct_id>NCT04622891</nct_id>
  </id_info>
  <brief_title>Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection</brief_title>
  <official_title>Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Valley University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Valley University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study was conducted at Qena Governorate, Egypt, during the period from May 2020,&#xD;
      to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly&#xD;
      assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500&#xD;
      /12 h for 7 days, or a control group with no antibiotics, All three groups received only&#xD;
      symptomatic treatment for control of fever and cough&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study was conducted at Qena Governorate, Egypt, during the period from May 2020,&#xD;
      to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly&#xD;
      assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500&#xD;
      /12 h for 7 days, or a control group with no antibiotics, All three groups received only&#xD;
      symptomatic treatment for control of fever and cough.&#xD;
&#xD;
      All study participants underwent full clinical evaluation including duration of fever, cough,&#xD;
      dyspnea, anosmia or GIT symptoms, C-reactive protein (CRP), serum ferritin, D-dimer, Complete&#xD;
      blood count (CBC), non-contrast chest computed tomography (CT) which was repeated 2 weeks&#xD;
      after the start of treatment.&#xD;
&#xD;
      The Azithromycin group included, 107 patients, mean age 45.8 ±18 years, 73 male and 34&#xD;
      female, the Clarithromycin group included 99 patients mean age 46.1±19 years, 68 males and 31&#xD;
      female, the control group included 99 patients, with mean age 41.1 ± 18 years, 73 male and 28&#xD;
      female.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">July 30, 2020</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>clarithomycin group Azithromycin group control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>time to fever control</measure>
    <time_frame>15 days</time_frame>
    <description>time to complete resolution of fever</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCR conversion</measure>
    <time_frame>15 days</time_frame>
    <description>time to PCR conversion from first positive PCR for COVID-19 to negative PCR</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clarithromycin group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azithromycin group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin 500mg</intervention_name>
    <description>clarithromycin 500</description>
    <arm_group_label>clarithromycin</arm_group_label>
    <other_name>active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>azithromycin group</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>active comparison</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>control group</description>
    <arm_group_label>control</arm_group_label>
    <other_name>control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COVID-19 cases&#xD;
&#xD;
          -  Oxygen saturation &gt; 93%&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt;18 years,&#xD;
&#xD;
          -  patients with Oxygen saturation &lt; 93%, patients with&#xD;
&#xD;
          -  Diabetes mellitus or&#xD;
&#xD;
          -  heart failure,&#xD;
&#xD;
          -  patients on chemotherapy or immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alaa Rashad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>associate professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>south-Vally University faculty of medicine</name>
      <address>
        <city>Qena</city>
        <zip>868532</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 7, 2020</last_update_submitted>
  <last_update_submitted_qc>November 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Valley University</investigator_affiliation>
    <investigator_full_name>Alaa Rashad</investigator_full_name>
    <investigator_title>Associate professor of chest diseases</investigator_title>
  </responsible_party>
  <keyword>Azithromycin</keyword>
  <keyword>clarithromycin</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

